
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc. is positioned for significant growth, as upcoming catalysts present potential value inflection points that could result in a substantial increase in stock value. The company's pipeline technology, particularly the drugs BDTX-4933 and BDTX-1535, demonstrates promising efficacy across a wide range of novel cancer mutations, including notable activity against actionable mutations like EGFR. Additionally, the lucrative opportunity within the first-line non-small cell lung cancer market, estimated to exceed $1 billion, reinforces expectations of positive financial performance in the near future.
Bears say
The financial outlook for Black Diamond Therapeutics Inc. is concerning due to the reduced confidence in the efficacy of its drug silevertinib, particularly in the context of the reported overall response rate (ORR) of 60%, which may not be replicable at lower doses. Additionally, the company's market capitalization of approximately $230 million reflects investor skepticism regarding silevertinib's competitiveness in the 1L EGFR-NCM patient population, compounded by high rates of treatment interruptions and adverse reactions. Overall, the disappointing clinical updates regarding the silevertinib's performance have led to a lack of confidence among investors, overshadowing other potential opportunities within the company's pipeline.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares